Top Markets
Coin of the day
Avalyn Pharma Inc. Common Stock Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc. Common Stock

AVLN
Rangering i aksjer #7324
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its... Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Aksjekurs
$36.75
Sist synkronisert: 2026-08-27
Markedsverdi
$1.63B
Endring (1 dag)
-0.78%
Endring (1 år)
-
Land
US
Handel Avalyn Pharma Inc. Common Stock (AVLN)

Kategori

P/B-forhold for Avalyn Pharma Inc. Common Stock (AVLN)
P/B-forhold per 2026 TTM: 0
Ifølge Avalyn Pharma Inc. Common Stock sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/B-forhold på 0.
P/B-historikk for Avalyn Pharma Inc. Common Stock fra 2026 til 2026
P/B-forhold ved hvert års slutt
År P/B-forhold Endre
Ikke nok data for de angitte datoene.
P/B-forhold for lignende selskaper eller konkurrenter
Selskap P/B-forhold Forskjell i P/B-forhold Land
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH